Tomoko Ise

2.8k total citations · 1 hit paper
47 papers, 2.3k citations indexed

About

Tomoko Ise is a scholar working on Molecular Biology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Tomoko Ise has authored 47 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 16 papers in Immunology and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Tomoko Ise's work include Monoclonal and Polyclonal Antibodies Research (12 papers), Toxin Mechanisms and Immunotoxins (7 papers) and Glycosylation and Glycoproteins Research (6 papers). Tomoko Ise is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (12 papers), Toxin Mechanisms and Immunotoxins (7 papers) and Glycosylation and Glycoproteins Research (6 papers). Tomoko Ise collaborates with scholars based in Japan, United States and Sweden. Tomoko Ise's co-authors include Hiroto Izumi, Kimitoshi Kohno, Minoru Nomoto, Hidetaka Uramoto, Satoshi Nagata, Tadashi Murakami, Mizuho Tanabe, Takayuki Torigoe, Yoichiro Yoshida and Hiroshi Ishiguchi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Blood.

In The Last Decade

Tomoko Ise

46 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy

2003 543 citations Hiroto Izumi, Takayuki Torigoe et al. profile →

Peers

Countries citing papers authored by Tomoko Ise

Since Specialization

Citations

This map shows the geographic impact of Tomoko Ise's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomoko Ise with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomoko Ise more than expected).

Fields of papers citing papers by Tomoko Ise

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomoko Ise. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomoko Ise. The network helps show where Tomoko Ise may publish in the future.

Co-authorship network of co-authors of Tomoko Ise

This figure shows the co-authorship network connecting the top 25 collaborators of Tomoko Ise. A scholar is included among the top collaborators of Tomoko Ise based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomoko Ise. Tomoko Ise is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule 2025 ·PubMed ·Hiroki Akiba, Tomoko Ise, (unknown), Yasuhiro Abe, Kouhei Tsumoto, Hiroaki Ohno, Haruhiko Kamada, Satoshi Nagata	0
2	Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo 2024 ·PLoS ONE ·(unknown), Kentaro Furukawa, Tomoko Ise, Masahiro Takayama, (unknown), Takayuki Kuroda, (unknown), Takashi Hashimoto, (unknown), Takeshi Ishihara, Masaaki Sato, Haruhiko Kamada, Keita Fukao, Takao Shishido, (unknown), Tatsuya Takahashi, Satoshi Nagata	2
3	Crystal structures of human CD40 in complex with monoclonal antibodies dacetuzumab and bleselumab 2024 ·Biochemical and Biophysical Research Communications ·(unknown), Makoto Nakakido, (unknown), Tomoko Ise, José M. M. Caaveiro, Satoshi Nagata, Kouhei Tsumoto	1
4	Production of IgG1-based bispecific antibody without extra cysteine residue via intein-mediated protein trans-splicing 2021 ·Scientific Reports ·Hiroki Akiba, Tomoko Ise, Satoshi Nagata, Haruhiko Kamada, Hiroaki Ohno, Kouhei Tsumoto	4
5	MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression 2016 ·Oncogene ·Sheema Khan, Mohammed Sikander, Mara C. Ebeling, Aditya Ganju, (unknown), Murali M. Yallapu, Bilal Bin Hafeez, Tomoko Ise, Satoshi Nagata, Nadeem Zafar, Stephen W. Behrman, Jim Y. Wan, (unknown), Peeyush Sahay, (unknown), Subhash C. Chauhan, Meena Jaggi	26
6	CD164 and FCRL3 Are Highly Expressed on CD4+CD26 − T Cells in Sézary Syndrome Patients 2013 ·Journal of Investigative Dermatology ·Maria Wysocka, Andrew V. Kossenkov, Bernice Benoit, Andrea B. Troxel, (unknown), András Schaffer, Brian Kim, Tzvete Dentchev, Satoshi Nagata, Tomoko Ise, Louise C. Showe, Alain H. Rook	31
7	Expression of POTE protein in human testis detected by novel monoclonal antibodies 2007 ·Biochemical and Biophysical Research Communications ·Tomoko Ise, Sudipto Das, Satoshi Nagata, Hiroshi Maeda, Yoomi Lee, Masanori Onda, Miriam R. Anver, Tapan K. Bera, Ira Pastan	14
8	Palmitoylation of POTE family proteins for plasma membrane targeting 2007 ·Biochemical and Biophysical Research Communications ·Sudipto Das, Tomoko Ise, Satoshi Nagata, Hiroshi Maeda, Tapan K. Bera, Ira Pastan	7
9	Impaired activity of volume‐sensitive Cl⁻ channel is involved in cisplatin resistance of cancer cells 2006 ·Journal of Cellular Physiology ·(unknown), Takahiro Shimizu, Tomoko Ise, Tomohiro Numata, Kimitoshi Kohno, Yasunobu Okada	74
10	Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera 2006 ·Clinical Chemistry and Laboratory Medicine (CCLM) ·Tomoko Ise, Robert J. Kreitman, Ira Pastan, Satoshi Nagata	6
11	Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma 2006 ·Leukemia ·Tomoko Ise, Satoshi Nagata, Robert J. Kreitman, Wyndham H. Wilson, Alan S. Wayne, Maryalice Stetler‐Stevenson, Michael Bishop, DA Scheinberg, Laura Z. Rassenti, Thomas J. Kipps, Robert A. Kyle, Diane F. Jelinek, Ira Pastan	50
12	Roles of Volume-sensitive Cl− Channel in Cisplatin-induced Apoptosis in Human Epidermoid Cancer Cells 2005 ·The Journal of Membrane Biology ·Tomoko Ise, Takahiro Shimizu, (unknown), H. Inoue, Kimitoshi Kohno, Yasunobu Okada	51
13	Rapid grouping of monoclonal antibodies based on their topographical epitopes by a label-free competitive immunoassay 2004 ·Journal of Immunological Methods ·Satoshi Nagata, Yoshito Numata, Masanori Onda, Tomoko Ise, Yoonsoo Hahn, Byung Kook Lee, Ira Pastan	23
14	p73 Interacts with c-Myc to Regulate Y-box-binding Protein-1 Expression 2002 ·Journal of Biological Chemistry ·Hidetaka Uramoto, Hiroto Izumi, Tomoko Ise, Mitsuhiro Tada, Takeshi Uchiumi, Michihiko Kuwano, Kosei Yasumoto, Keiko Funa, Kimitoshi Kohno	81
15	Human mitochondrial transcription factor A binds preferentially to oxidatively damaged DNA 2002 ·Biochemical and Biophysical Research Communications ·Yoichiro Yoshida, Hiroto Izumi, Tomoko Ise, Hidetaka Uramoto, Takayuki Torigoe, Hiroshi Ishiguchi, Tadashi Murakami, Mizuho Tanabe, Yoshifumi Nakayama, Hideaki Itoh, Hiroshi Kasai, Kimitoshi Kohno	57
16	Enhanced Expression of the Human Vacuolar H+-ATPase c subunit Gene (ATP6L) in Response to Anticancer Agents 2002 ·Journal of Biological Chemistry ·Takayuki Torigoe, Hiroto Izumi, Hiroshi Ishiguchi, Hidetaka Uramoto, Tadashi Murakami, Tomoko Ise, Yoichiro Yoshida, Mizuho Tanabe, Minoru Nomoto, Hideaki Itoh, Kimitoshi Kohno	71
17	Interaction with p53 Enhances Binding of Cisplatin-modified DNA by High Mobility Group 1 Protein 2001 ·Journal of Biological Chemistry ·Toshihiro Imamura, Hiroto Izumi, Gunji Nagatani, Tomoko Ise, Minoru Nomoto, Yukihide Iwamoto, Kimitoshi Kohno	84
18	Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression 2000 ·Oncogene ·Tatsuro Okamoto, Hiroto Izumi, Toshihiro Imamura, Hiroshi Takano, Tomoko Ise, Takeshi Uchiumi, (unknown), (unknown)	131
19	Structure and functional analysis of the human STAT3 gene promoter: alteration of chromatin structure as a possible mechanism for the upregulation in cisplatin-resistant cells 2000 ·Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression ·Ken Kato, Minoru Nomoto, Hiroto Izumi, Tomoko Ise, Shuji Nakano, Yoshiyuki Niho, Kimitoshi Kohno	33
20	Structural Characterization of the Human Interleukin-13 Receptor α1 Gene Promoter 1999 ·Biochemical and Biophysical Research Communications ·Tomoko Ise, Hiroto Izumi, Gunji Nagatani, Hiroshi Takano, Morimasa Wada, Michihiko Kuwano, Kimitoshi Kohno	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact